Some issues of the diagnosis and treatment of gastroesophageal reflux disease

Cite item

Full Text


The clinical inefficacy of proton pump inhibitors (PPIs) is very frequently encountered in nonerosive gastroesophageal reflux disease (NERD) in particular. Postprandial acid pocket, weak-acid or alkaline reflux, etc. are one of the causes of resistance to antisecretory drugs. Alginates serve as a good alternative to PPIs in treating NERD and gastroesophageal reflux in children and pregnant women. The alginate test may help diagnose NERD.

About the authors

V G Avdeev


  1. Vakil N, van Zanten SV, Kahrilas P. The Montreal definition and classification of gastro-esophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101(8):1900-1920.
  2. Маев И.В., Трухманов А.С. Лекарственная терапия неэрозивной рефлюксной болезни. Русский медицинский журнал. 2004;12(24):1402-1409.
  3. Drossman D Rome III. The functional gastrointestinal disorders. McLean V.A.: Degnon Associates, Inc. 2006.
  4. Кайбышева В.О., Трухманов А.С., Ивашкин В.Т. Гастроэзофагеальная рефлюксная болезнь, резистентная к терапии ингибиторами протонной помпы. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2011;ХХI(4): 4-13.
  5. Dean BB, Gano Jr AD, Knight K. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol. 2004;2:656-664.
  6. Liker HR, Ducrotter P, Malfertheiner P. Unmet medical needs among patients with gastroesophageal reflux disease: a foundation for improving management in primary care. Dig Dis. 2009;27: 62-67.
  7. Mastronarde JG, Anthonisen NR, Castro M. Efficacy of esomeprazole for treatment of poorly controlled asthma. N Engl J Med. 2009;360:1487-1499.
  8. Frieling T. Antireflux therapy — more than acid reduction. Internist(Berl). 2004;45:1364-1369.
  9. Fass R, Shapiro M, Dekel R. Systematic review: proton pump inhibitor failure in gastroesophageal reflux disease — where next? AlimentPharmacol Ther. 2005;22:79-94.
  10. Barrison AF, Jarbe LA, Weinberg MD et al. Patterns of proton pump inhibitors in clinical practice. Am J Med. 2001;111:469-473.
  11. Pezanoski J, Guanaratnam N, Cowen M. Correct and incorrect dosing of proton pump inhibitors and its impact on GERD symptoms. Gastroenterology. 2003;124(suppl.):128.
  12. Hatlebakk JG, Katz PO, Camacho-Lobato L et al. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther. 2000;14:1267-1272.
  13. Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut. 2009;58:295-309.
  14. Furuta Т, Shirai N, Watanabe F et al. Effect of cyto-chrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprasole. Clin Pharmacol Ther. 2002;72:453-460.
  15. Fletcher J, Wirz A, Young J, Vallance R, McColl KE. Unbuffered highly acidic gastric juice exists at the gastroesophageal junction after a meal. Gastroenterology. 2001;121(4):775-783.
  16. Rohof WO, Bennink RJ, de Ruigh AA, Hirsch DP, Zwinderman AH, Boeckxstaens GE. Effect of azithromycin on acid reflux, hiatus hernia and proximal acid pocket in the postprandial period. Gut. 2012;61(12):1670-1677. doi: 10.1136/gutjnl-2011-300926.
  17. Rohof WO, Bennink RJ, Smout AJ, Thomas E, Boeckxstaens GE. An alginate-antacid formulation localizes to the acid pocket to reduce acid reflux in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2013;11(12):1585-1591; quiz e90. doi: 10.1016/j.cgh.2013.04.046.
  18. Curcic J, Schwizer A, Kaufman E, Forras-Kaufman Z, Banerjee S, Pal A, Hebbard GS, Boesiger P, Fried M, Steingoetter A, Schwizer W, Fox M. Effects of baclofen on the functional anatomy of the oesophago-gastric junction and proximal stomach in healthy volunteers and patients with GERD assessed by magnetic resonance imaging and high-resolution manometry: a randomised controlled double-blind study. Aliment PharmacolTher. 2014; 40(10):1230-1240. doi: 10.1111/apt.12956.
  19. Kwiatek M, Roman S, Fareeduddin A. An alginate-antacid formulation (Gaviscon Double Action Liquid) can eliminate or displace the postprandial ‘acid pocket’ in symptomatic GERD patients. Aliment PharmacolTher. 2011;34(1):59-66.
  20. Бордин Д.С, Машарова А.А., Фирсова Л.Д., Кожурина Т.С., Сафонова О.В. Оценка эффективности альгинат-рафтового барьера в лечении гастроэзофагеальной рефлюксной болезни. Экспериментальная и клиническая гастроэнтерология. 2008;6:77-81.
  21. Бордин Д.С., Машарова А.А., Дроздов В.Н., Фирсова Л.Д., Кожурина Т.С. Диагностическое значение альгинатного теста при гастроэзофагеальной рефлюксной болезни. Экспериментальная и клиническая гастроэнтерология. 2010;12: 102-107.
  22. Strugala V, Dettmar PW, Sarratt K, Sykes J, Berry P, Thomas E. A randomized, controlled, crossover trial to investigate times to onset of the perception of soothing and cooling by over-the-counter heartburn treatments. J Int Med Res. 2010;38:449-457.
  23. De Ruigh A, Roman S, Chen J, Pandolfino JE, Kahrilas PJ. Gaviscon Double Action Liquid (antacid & alginate) is more effective than antacid in controlling post-prandial oesophageal acid exposure in GERD patients: a double-blind crossover study. Aliment Pharmacol Ther. 2014;40(5):531-537. doi: 10.1111/apt.12857.
  24. Mandel KG, Daggy BP, Brodie DA, Jacoby HI. Review article: alginate-raft formulations in the treatment of heartburn and acid reflux. AlimentPharmacol Ther. 2000;14:669-690.
  25. Manabe N, Haruma K, Ito M, Takahashi N et al. Efficacy of adding sodium alginate to omeprazole in patients with nonerosive reflux disease: a randomized clinical trial. Dis Esophagus. 2012;25(5):373-380.
  26. Dettmar PW, Hampson FC, Jain A, Choubey S, Little SL, Baxter T. Administration of an alginate based gastric reflux suppressant on the bioavailability of omeprazole. Indian J Med Res. 2006; 123(4):517-524.
  27. Шептулин А.А. Современные возможности и перспективы лечения резистентных форм гастроэзофагеальной рефлюксной болезни. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2010;20(6):81-85.
  28. Reddy H, Staahl C, Arendt-Nielsen L et al. Sensory and biomechanical properties of the esophagus in nonerosive reflux disease. Scand J Gastroenterol. 2007;42:432-440.
  29. Trimble KC, Pryde A, Heading RC. Lowered esophageal sensory thresholds in patients with symptomatic but not excess gastroesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD. Gut. 1995;37:7-12.
  30. Tack J, Koek G, Demedts I et al. Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett’s esophagus: acid reflux, bile reflux, or both? Am J Gastroenterol. 2004;99:981-989.
  31. Hershcovici Т, Fass R. Nonerosive Reflux Disease (NERD) — An Update. J Neurogastroenterol Motil. 2010;16(1):8-21, 39.
  32. Pace F, Pace M. The proton pump inhibitor test and the diagnosis of gastroesophageal reflux disease. Expert Rev Gastroenterol Hepatol. 2010;4(4):423-427.
  33. Remes-Troche J.M., Carmona-Sanchez R., Soto Perez J.C. et al. Utility of rabeprazole as a diagnostic test in non-erosive gastroesophageal reflux disease. Rev Gastroenterol Mex. 2005;70(3): 276-283.
  34. Jones R, Junghard O, Dent J, et al. Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care. Aliment Pharmacol Ther. 2009;30(10):1030-1038.
  35. Кайбышева В.О., Кучерявый Ю.А., Трухманов А.С., Сторонова О.А., Коньков М.Ю., Маев И.В., Ивашкин В.Т. Результаты многоцентрового наблюдательного исследования по применению международного опросника GerdQ для диагностики ГЭРБ. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2013;5:15-23.
  36. Gawron AJ, Rothe J, Fought AJ, Fareeduddin A, Toto E, Boris L, Kahrilas PJ, Pandolfino JE. Many patients continue using proton pump inhibitors after negative results from tests for reflux disease. ClinGastroenterol Hepatol. 2012;10(6):620-625; quiz e57. doi: 10.1016/j.cgh.2012.02.012.
  37. Smout AJ, Geus WP, Mulder PG, Stockbrügger RW, Lamers CB. Gastro-oesophageal reflux disease in The Netherlands. Results of a multicentre pH study. Scand J Gastroenterol 1996;218(suppl):10-15.
  38. Kapadia CJ, Mane VB. Raft-forming agents: antireflux formulations. Drug Dev Ind Pharm. 2007;33(12):1350-1361.
  39. Елохина Т.Б., Тютюнник В.Л. Гастроэзофагеальная рефлюксная болезнь при беременности. Русский медицинский журнал. 2008;16(19):1243-1247.
  40. Richter JE. Review article: the management of heartburn in pregnancy. Aliment Pharmacol Ther. 2005;22(9):749-757.
  41. Rey E, Rodriguez-Artalejo F, Herraiz MA et al. Gastroesophageal reflux symptoms during and after pregnancy: alongitudinal study. Am J Gastroenterol. 2007;102(11):2395-2400.
  42. Bor S, Kitapcioglu G, Dettmar P, Baxter T, Association of heartburn during pregnancy with the risk of gastroesophageal reflux disease. Clin GastroenterolHepatol. 2007;5(9):1035-1039.
  43. Lang GD, Dougall A. Comparative study of Algicon suspension and magnesium trisilicate mixture in the treatment of reflux dyspepsia of pregnancy. Br J Clin Pract. 1990;66:48-51.
  44. Uzan M, Uzan S, Surean C, Richard-Berthe C. Heartburn and regurgitation in pregnancy, efficacy and innocuousness of treatment with Gaviscon suspension. Rev Fr Gynecol Obstet. 1988;83:569-572.
  45. Lindow SW, Regnell P, Sykes J, Little S. An open-label, multicentre study to assess the safety and efficacy of a novel reflux suppressant (Gaviscon Advance) in the treatment of heartburn during pregnancy. Int JClin Pract. 2003;57(3):175-179.
  46. Strugala V, Bassin J, Swales VS, Lindow SW, Dettmar PW, Thomas ECM. Clinical Study Assessment of the Safety and Efficacy of a Raft-Forming Alginate Reflux Suppressant (Liquid Gaviscon) for the Treatment of Heartburn during Pregnancy International Scholarly Research Network ISRN. Obstet Gynecol. 2012; 2012:Article ID 481870, 6 pages. doi: 10.5402/2012/481870
  47. Nelson SP, Chen EH, Syniar GM et al. One-year follow-up of symptoms of gastroesophageal reflux during infancy. Pediatric Practice Research Group. Pediatrics. 1998;102:67.
  48. Chitkara DK, Talley NJ, Weaver AL et al. Incidence of presentation of common functional gastrointestinal disorders in children from birth to 5 years: A cohort study. Clin Gastroenterol Hepatol. 2007;5(2):186-191.
  49. De S, Rajeshwari K, Kalra KK et al. Gastroesophageal reflux in infants and children in North India. Trop Gastroenterol. 2001;22:99-102.
  50. Miyazawa R, Tomomasa T, Kaneko H et al. Prevalence of gastroesophageal reflux-related symptoms in Japanese infants. Pediatr Int. 2002;44:513-516.
  51. Nelson SP, Chen EH, Syniar GM et al. One-year follow-up of symptoms of gastroesophageal reflux during infancy. Pediatric Practice Research Group. Pediatrics. 1998;102:67.
  52. Martin AJ, Pratt N, Kennedy JD et al. Natural history and familial relationships of infant spilling to 9 years of age. Pediatrics. 2002;109:1061.
  53. Gilger M.A., El-Serag H.B., Gold B.D. et al. Prevalence of endoscopic findings of erosive esophagitis in children: a population-based study. J Pediatr Gastroenterol Nutr. 2008;47:141-146.
  54. Gunasekaran TS, Dahlberg M, Ramesh P, Namachivayam G. Prevalence and associated features of gastroesophageal reflux symptoms in a Caucasian-predominant adolescent school population. Dig Dis Sci. 2008;53(9):2373-2379.
  55. Osatakul S, Sriplung H, Puetpaiboon A et al. Prevalence and natural course of gastroesophageal reflux symptoms: a 1-year cohort study in Thai infants. J Pediatr Gastroenterol Nutr. 2002;34:63-67.
  56. Rudolph CD, Mazur LJ, Liptak GS et al. Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children: recommendations of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr. 2001;32(2):1.
  57. Shaheen N, Ransohoff DF. Gastroesophageal reflux, barrett esophagus, and esophageal cancer: scientific review. JAMA. 2002;287(15):1972-1981.
  58. Tolia V, Wuerth A, Thomas R. Gastroesophageal reflux disease: review of presenting symptoms, evaluation, management and outcome in infants. Dig Dis Sci. 2003;9(48):1723-1729.
  59. Мухаметова Е.М., Эрдес С.И., Щербаков П.Л. и др. Оценка клинической эффективности альгинатсодержащего препарата Гевискон (суспензия) у детей с различными эндоскопическими вариантами ГЭРБ. Эффективная фармакотерапия. Гастроэнтерология. 2011;5:8-14.
  60. Mandel KG, Daggy BP, Brodie DA, Jacoby HI. Review article: alginate-raft formulations in the treatment of heartburn and acid reflux. AlimentPharmacol Ther. 2000;14:669-690.

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail:


© 2018-2021 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies